Literature DB >> 8566581

Expression of variant CD44-messenger RNA in colorectal adenocarcinomas and adenomatous polyps in humans.

F Imazeki1, O Yokosuka, T Yamaguchi, M Ohto, K Isono, M Omata.   

Abstract

BACKGROUND & AIMS: Recent studies have shown that some variant forms of CD44, a transmembrane glycoprotein expressed on various cell surfaces, might be involved in tumor progression or tumor metastasis. The aim of this study was to analyze the expression of CD44-messenger RNA (mRNA) in colorectal cancer and colorectal adenoma to further elucidate the role of CD44 in colorectal tumorigenesis.
METHODS: The expression of CD44-mRNA was examined in 90 specimens from 44 patients with colorectal cancer or colorectal adenomatous polyps and in the peripheral blood leukocytes from 7 healthy volunteers by reverse transcription-polymerase chain reaction and Southern blot hybridization.
RESULTS: Strong expression of the epithelial form and variant forms containing exons 11 or 12 of the CD44 gene, which conferred metastatic behavior to rat cells, was detected in primary and metastatic tumor tissues, whereas it was very weak or not detectable in normal colonic mucosae, normal liver tissue, or peripheral blood leukocytes. However, adenomatous colorectal polyps also showed as strong an expression of epithelial and variant forms of CD44 as primary and metastatic tumor tissues.
CONCLUSIONS: These results suggest that variant forms of CD44-mRNA might be expressed in an early stage of colorectal carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8566581     DOI: 10.1053/gast.1996.v110.pm8566581

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  13 in total

1.  CD44 variant exons in leukemia and lymphoma.

Authors:  Elif Akisik; Sevil Bavbek; Nejat Dalay
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

2.  FAK, CD44v6, c-Met and EGFR in colorectal cancer parameters: tumour progression, metastasis, patient survival and receptor crosstalk.

Authors:  Alexandros Garouniatis; Adamantia Zizi-Sermpetzoglou; Spyros Rizos; Alkiviadis Kostakis; Nikolaos Nikiteas; Athanasios G Papavassiliou
Journal:  Int J Colorectal Dis       Date:  2012-06-26       Impact factor: 2.571

Review 3.  Forms and functions of CD44.

Authors:  G Borland; J A Ross; K Guy
Journal:  Immunology       Date:  1998-02       Impact factor: 7.397

Review 4.  CD44 and HCELL: preventing hematogenous metastasis at step 1.

Authors:  Pieter P Jacobs; Robert Sackstein
Journal:  FEBS Lett       Date:  2011-08-05       Impact factor: 4.124

5.  Gastrin and gastrin receptor activation: an early event in the adenoma-carcinoma sequence.

Authors:  A M Smith; S A Watson
Journal:  Gut       Date:  2000-12       Impact factor: 23.059

6.  Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway.

Authors:  V J Wielenga; R Smits; V Korinek; L Smit; M Kielman; R Fodde; H Clevers; S T Pals
Journal:  Am J Pathol       Date:  1999-02       Impact factor: 4.307

Review 7.  Beta-catenin--a linchpin in colorectal carcinogenesis?

Authors:  Newton Alexander Chiang Shuek Wong; Massimo Pignatelli
Journal:  Am J Pathol       Date:  2002-02       Impact factor: 4.307

8.  Purification of total RNA from human stool samples.

Authors:  R J Alexander; R F Raicht
Journal:  Dig Dis Sci       Date:  1998-12       Impact factor: 3.199

9.  Expression of CD44s in human colorectal cancer.

Authors:  Mousa Khoursheed; T C Mathew; R R Makar; L Sonia; H Abul; S Asfar; H Al-Sayer; H M Dashti; A Al-Bader
Journal:  Pathol Oncol Res       Date:  2003-01-06       Impact factor: 3.201

10.  CD44v6 down-regulation is an independent prognostic factor for poor outcome of colorectal carcinoma.

Authors:  Lili Wang; Qin Liu; Dongliang Lin; Maode Lai
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.